Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
Longeveron Inc. - Class A Common stock (LGVN)
Company Research
Source: GlobeNewswire
Findings offer potential mechanistic and clinical insights in the development of cellular therapy Lomecel-B™ for mild Alzheimer’s disease (AD)Lomecel-B™ capacity to inhibit MMP14 correlates with improved clinical and biomarker outcomes in mild ADImmunomodulatory and pro-vascular effects of Lomecel-B™ in mild AD potentially driven by ability to exert MMP14 inhibition which may protect TIE2 receptor integrity in human AD patients MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that its submission entitled “Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer’s disease” was presented as a late breaking poster presentation at the 17th edition of the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) taking place October 29 -November
Show less
Read more
Impact Snapshot
Event Time:
LGVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGVN alerts
High impacting Longeveron Inc. - Class A Common stock news events
Weekly update
A roundup of the hottest topics
LGVN
News
- Longeveron to Present at Biotech Showcase 2025 [Yahoo! Finance]Yahoo! Finance
- Longeveron to Present at Biotech Showcase 2025GlobeNewswire
- Longeveron Inc. (NASDAQ: LGVN) was upgraded by analysts at Roth Capital to a "strong-buy" rating.MarketBeat
- Longeveron Inc. (NASDAQ: LGVN) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024GlobeNewswire
LGVN
Earnings
- 11/12/24 - Beat
LGVN
Sec Filings
- 12/4/24 - Form 4
- 11/27/24 - Form 144
- 11/14/24 - Form SC
- LGVN's page on the SEC website